Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BackgroundInhibition of the renin–angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies. ObjectiveThe objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC). MethodsPatients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses. ResultsIn the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo); p = 0.014) and remained a significant prognostic factor upon multivariate analysis (HR = 0.6; 95% CI 0.4–0.9; p = 0.011). In subgroup analysis, patients treated with sorafenib plus RASi had better median OS (19.5 mo) compared to those treated with either sorafenib (10.9 mo) or RASi (9.7 mo) alone (p = 0.043). The beneficial effect of RASi on survival was confirmed in the Mainz cohort (n = 76).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 1×
“Hence, the desmoplastic milieu can promote resistance to immunotherapy.(34,35) Additionally, tumor desmoplasia contributes to blood vessel compression by increasing tissue stiffness and solid stress.”
BackgroundAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“The reduced tumor perfusion and the resulting hypoxia further support the immunosuppressive microenvironment, promote the selection of more invasive tumor cells, and lower the efficacy of certain treatment modalities.(30,36,37) In several solid malignancies including cholangiocarcinoma, tumor desmoplasia occurs as a s…”
BackgroundSelf-citationGene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationThe Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044 · cited 1×
“The reduced tumor perfusion and the resulting hypoxia further support the immunosuppressive microenvironment, promote the selection of more invasive tumor cells, and lower the efficacy of certain treatment modalities.(30,36,37) In several solid malignancies including cholangiocarcinoma, tumor desmoplasia occurs as a s…”
BackgroundSelf-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 2×
“In several solid malignancies including cholangiocarcinoma, tumor desmoplasia occurs as a secondary event in response to tumor growth, wherein malignant cells drive stromal fibroblasts to produce and deposit ECM.(27,30,38) In contrast, liver fibrosis and cirrhosis represent a procarcinogenic microenvironment that prom…”
BackgroundSelf-citationHepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.011 · Cited by 603 · cited 1×
“HCC usually develops in patients with underlying liver cirrhosis, predominantly caused by chronic viral hepatitis or alcohol consumption, and nonalcoholic steatohepatitis (NASH) as rapidly growing cause in Western countries.(5) Treatment of HCC depends on tumor stage, liver function, and general condition of the patie…”
BackgroundGonzález-Abraldes, J., Albillos, A., Bañares, R., Del Arbol, L. R., Moitinho, E., Rodríguez, C., González, M., Escorsell, A., García-Pagán, J. C., & Bosch, J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26288 · Cited by 165
Cited by
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Self-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
Self-citationTargeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Self-citation
Metadata
- Authors
- Pinter, M., Weinmann, A., Wörns, M.-A., Hucke, F., Bota, S., Marquardt, J. U., Duda, D. G., Jain, R. K., Galle, P. R., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W.
- Venue
- United European Gastroenterology Journal
- Publisher
- Wiley
- Published
- 2017-02-26
- Volume
- 5
- Issue
- 7
- Pages
- 987-996
- ISSN
- 2050-6406 (ISSN-L)
- 2050-6414
- OpenAlex
- W2592981965
- Cited by
- 55
- References
- 8
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. https://app.cochat.ai/papers/10.1177/2050640617695698
- The paper
- Pinter, M., Weinmann, A., Wörns, M.-A., Hucke, F., Bota, S., Marquardt, J. U., Duda, D. G., Jain, R. K., Galle, P. R., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W. (2017). Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterology Journal. https://doi.org/10.1177/2050640617695698
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.